IP
ALXN

Intellectus Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Intellectus Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,942
Closed -$357K – 287
2021
Q2 		$357K Sell
1,942
-342
-15% -$58.7K 0.08% 217
2021
Q1 		$349K Sell
2,284
-251
-10% -$38.8K 0.1% 205
2020
Q4 		$396K Sell
2,535
-823
-25% -$106K 0.12% 177
2020
Q3 		$384K Buy
3,358
+823
+32% +$88.8K 0.15% 160
2020
Q2 		$285K Hold
2,535
– – 0.11% 177
2020
Q1 		$228K Buy
+2,535
New +$249K 0.11% 174
2017
Q3 		– Sell
-36
Closed -$14K – 815
2017
Q2 		$14K Buy
+36
New +$4.19K 0.01% 554

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Intellectus Partners's ALXN Position: Q3 2021 in Review

Intellectus Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,942 shares — an estimated $357K sold.

Intellectus Partners first reported a position in ALXN in Q2 2017 and held it in 7 quarters. The position peaked at $396K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Intellectus Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Intellectus Partners sold 1,942 Alexion Pharmaceuticals shares in Q3 2021, an estimated $357K.
  • Intellectus Partners first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 7 quarters.
  • Intellectus Partners's Alexion Pharmaceuticals position peaked at $396K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Intellectus Partners's 13F filing for Q3 2021, filed 16 Nov 2021.